Technology
Health
Pharmaceutical

Zynerba Pharmaceuticals

$5.94
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.37 (-6.02%) Today
+$0.16 (2.77%) After Hours

Why Robinhood?

You can buy or sell ZYNE and other stocks, options, ETFs, and crypto commission-free!

About

Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. It engages in the development and commercialization of transdermal pharmaceutically-produced cannabinoid treatments for rare and near-rare neurological and psychiatric, or neuropsychiatric, disorders in patients with high unmet medical needs. Read More The company was founded by Audra L. Stinchcomb on January 31, 2007 and is headquartered in Devon, PA.

Employees
25
Headquarters
Devon, Pennsylvania
Founded
2007
Market Cap
101.88M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
553.12K
High Today
$6.14
Low Today
$5.66
Open Price
$6.11
Volume
433.15K
52 Week High
$12.50
52 Week Low
$2.75

Collections

Technology
Health
Pharmaceutical
Medical
2015 IPO
US
North America

News

Simply Wall StMar 21

Have Insiders Been Buying Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) Shares?

We’ve lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On the other hand, we’d be remiss not to mention that insider sales have been known to precede tough periods for a business. So before you buy or sell Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), you may well want to know whether insiders have been buying or selling. Do Insider Transactions Matter? Most investors know that it is quite permissible for company leaders, such as directors of the ...

4,102
Yahoo FinanceMar 20

These Four Marijuana Stocks Are Bringing The Heat On Wednesday

CORAL GABLES, FL / ACCESSWIRE / March 20, 2019 / The marijuana stock market has exhibited great promise in the month of March, resulting in the excitement surrounding the cannabis industry.

6,772
BenzingaMar 11

Zynerba Pharmaceuticals (NASDAQ:ZYNE) Adds Autism, DiGeorge Syndrome To Pipeline

Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) beat the consensus estimate for its fourth-quarter loss Monday and provided some highlights from its ongoing and upcoming trials.

4,798

Earnings

-$0.91
-$0.75
-$0.60
-$0.44
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.65 per share
Actual
-$0.44 per share

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.